AI Mental Health Chatbots: Wysa, Woebot, Replika in 2026

Mental health chatbots are not all the same product, and the clinical evidence for them varies by an order of magnitude. Wysa (NHS-deployed, FDA Breakthrough Device designation, peer-reviewed RCTs) and Woebot (the original CBT chatbot, FDA Breakthrough Device for postpartum depression) sit in one category — clinical-grade, evidence-validated, regulated. Replika sits in a different category entirely — companion AI with minimal clinical evidence and a history of safety controversies. Conflating them does real harm to users and to the field.

The 2025 narrative review in JMIR Mental Health summarized the state of the literature: cognitive-behavioral-therapy-based chatbots produce statistically meaningful reductions in depression and anxiety symptoms in short-duration trials, with effect sizes in the small-to-moderate range and clinical engagement metrics (drop-out, adherence) comparable to in-person CBT cohorts. The headline: the tech category is real, the evidence is real, and the field has matured past the early skeptical phase.

Wysa — the deepest clinical-evidence position

Wysa is a UK-based CBT chatbot deployed by the NHS as a first-line digital mental-health service. It holds FDA Breakthrough Device designation (granted 2022 for adolescent depression and anxiety) and has published 15+ peer-reviewed efficacy studies across depression, anxiety, chronic pain co-morbidity, and maternal mental health. Wysa's clinical positioning is the most rigorous in the category — its evidence pipeline looks more like a digital therapeutic than a wellness app.

Wysa's product is a structured CBT progression: the user describes their state, Wysa identifies the cognitive distortion pattern (catastrophizing, all-or-nothing thinking, mind-reading), and walks the user through Socratic-questioning prompts to reframe the thought. The system escalates to human coaches (Wysa offers paid access to licensed therapists) when self-harm or crisis signals are detected. Several health-plan benefits programs in the U.S. now include Wysa as a covered service.

Woebot — the original, and the cautionary tale

Woebot launched in 2017 with the seminal randomized controlled trial that put CBT chatbots on the map — two weeks of Woebot use produced statistically significant depression and anxiety symptom reductions vs a control group. The company subsequently raised significant venture capital, secured FDA Breakthrough Device designation for postpartum depression, and was the public face of clinical-grade chatbot mental health for years.

In 2024–25 Woebot Health pivoted significantly, reducing direct-to-consumer marketing and refocusing on enterprise health-system contracts. The reasons reportedly included margin pressure from competing products and the regulatory complexity of consumer-facing mental health devices. Woebot the technology is still effective; Woebot the business has narrowed its commercial focus. Their CBT methodology and published evidence remains the most-cited reference for the entire category.

Replika — the category-confusion problem

Replika is a companion AI, not a therapy product. Its core proposition is conversational companionship — a relational-AI persona that learns the user's preferences and engages in long-running emotional conversations. The product has been marketed adjacent to mental-health benefits ("feel less lonely," "always there to listen") but does not deliver structured CBT, has minimal clinical efficacy evidence, and has been the subject of repeated safety incidents — including reports of the bot encouraging self-harm in vulnerable users and, separately, a 2023 sexual-content scandal that led to user backlash and a major product reset.

Replika belongs in the same conversation as Wysa and Woebot because users frequently use it for the same purposes — managing loneliness, navigating relationship anxiety, processing daily stress. But the underlying engineering, evidence base, and safety posture are categorically different. The pragmatic recommendation: if a user is reaching for a chatbot for mental-health support, Wysa or Woebot's clinical-grade products are the appropriate choice. Replika is appropriate for companionship use cases where therapeutic outcomes are not the goal.

Side-by-side

Platform	Category	FDA status	Published RCT evidence	Safety posture
Wysa	CBT chatbot	Breakthrough Device (2022, adolescent)	15+ peer-reviewed studies	Crisis-escalation to human coaches built-in
Woebot	CBT chatbot	Breakthrough Device (postpartum depression)	Foundational 2017 RCT + follow-ups	Strong; pivoted to enterprise focus 2024–25
Replika	Companion AI	None	Minimal therapeutic efficacy data	Mixed; history of safety incidents

The regulatory landscape and what's changing

FDA Breakthrough Device designation is not the same as full clearance — it accelerates the regulatory pathway but does not constitute approval. Both Wysa and Woebot are pursuing full Class II clearance under the FDA's digital therapeutic framework, which would put them in the same regulatory category as Pear Therapeutics' (now Click Therapeutics) reSET addiction-treatment software or Akili's EndeavorRx ADHD product. Full clearance unlocks payer reimbursement at scale, which is the bottleneck for broader U.S. adoption.

The European posture is different — the UK's NICE (National Institute for Health and Care Excellence) and Germany's DiGA digital-therapeutics framework both already provide reimbursement pathways for evidence-backed mental-health chatbots, which is why Wysa's commercial footprint there is larger than its U.S. footprint. The U.S. is catching up but slower.

What practitioners should actually recommend

For clinicians or benefits administrators choosing a chatbot to recommend:

• Mild-to-moderate depression or anxiety, treatment-seeking adult: Wysa (English-language) or Woebot (where still consumer-available). Pair with a human-therapist track if symptoms persist.
• Adolescent population: Wysa specifically (its adolescent-focused Breakthrough Device designation is the strongest evidence). Parental-consent workflow built-in.
• Postpartum depression: Woebot — its specific Breakthrough designation is for this indication.
• Maternal mental health, chronic pain co-morbidity: Wysa — published evidence specifically for these populations.
• Loneliness, social-connection need (not therapeutic): Companion AI like Replika may be appropriate, but explicitly not as a substitute for clinical care.

The broader healthcare-AI pattern continues, as covered in our analysis of medication management systems and the AI health coach landscape: clinical-grade AI is consolidating around vendors with regulatory rigor, peer-reviewed evidence, and integrated escalation paths. Wellness-adjacent products that lean on AI without the clinical infrastructure should not be conflated.

The bottom line

The 2026 mental-health chatbot market has stratified cleanly. Wysa and Woebot are clinical-grade, evidence-validated, FDA-track products that fit alongside structured care. Replika is a companion AI with a different value proposition and a weaker safety record — it should not be recommended for users seeking therapeutic support. The accuracy and severity of this distinction matters: it determines who gets actual symptom improvement and who gets a marketed-as-therapy product that may worsen outcomes in vulnerable populations.

Frequently Asked Questions

Is Wysa FDA-approved?

Wysa has FDA Breakthrough Device designation (granted 2022) for adolescent depression and anxiety, which accelerates the regulatory pathway but is not full clearance. Wysa is pursuing full Class II clearance under the FDA's digital therapeutic framework. In the UK, Wysa is deployed by the NHS as a first-line digital mental-health support tool.

What is the evidence that Woebot actually works?

The foundational 2017 randomized controlled trial showed two weeks of Woebot use produced statistically significant reductions in depression and anxiety symptoms vs a control group. Multiple follow-up studies replicated the effect across different populations. Woebot Health holds FDA Breakthrough Device designation specifically for postpartum depression. The 2025 JMIR narrative review confirmed CBT-chatbot efficacy effect sizes in the small-to-moderate clinical range.

Why is Replika different from Wysa or Woebot?

Replika is a companion AI, not a therapy chatbot. It does not deliver structured cognitive-behavioral therapy, lacks the published clinical efficacy data that Wysa and Woebot have built, and has a more mixed safety history including documented incidents of unsafe content. Replika may be appropriate for companionship use cases but should not be recommended as a substitute for clinical mental-health care.

Can mental-health chatbots replace a therapist?

No, and the responsible vendors do not claim they can. Wysa and Woebot are positioned as adjuncts to traditional care for mild-to-moderate symptoms, plus first-line support where in-person therapy access is constrained (waitlists, geographic limits, cost barriers). For moderate-to-severe symptoms, suicidal ideation, or serious mental illness, in-person clinical care is the appropriate path; chatbots can serve as a bridge but not a replacement.

Does my health insurance cover Wysa or Woebot?

In the U.S., coverage is uneven and growing — several employer-sponsored health benefits programs now include Wysa as a covered service; Woebot's enterprise pivot focuses on health-plan and self-insured-employer contracts. Direct individual reimbursement through major U.S. insurers is rare today but expected to expand as the products approach full FDA clearance. In the UK and Germany, the NHS and DiGA frameworks already provide structured reimbursement pathways.